MNPR (STOCKS)
Monopar Therapeutics Inc. Common Stock
$56.080000
+0.000000 (+0.00%)
Prev close: $56.080000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Chandler Drew Robinson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $375.30M
- Employees
- 16
- P/E (TTM)
- -28.24
- P/B (TTM)
- 2.72
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
14
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.64 | $-0.50 | -0.1372 | -27.29% |
|
Sep 2025 (Q3)
|
$-0.48 | $-0.44 | -0.0414 | -9.44% |
|
Jun 2025 (Q2)
|
$-0.35 | $-0.48 | +0.1314 | +27.30% |
|
Mar 2025 (Q1)
|
$-0.38 | $-0.69 | +0.3136 | +45.21% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $16.70M |
| Research and Development | $9.90M |
| Other Operating Expenses | $6.80M |
| Operating Income/Loss | -$16.70M |
| Income/Loss From Continuing Operations After Tax | -$13.72M |
| Income/Loss From Continuing Operations Before Tax | -$13.72M |
| Income Tax Expense/Benefit | $800.00 |
| Income Tax Expense/Benefit, Current | $800.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$13.72M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.72M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.72M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.85 |
| Basic Average Shares | 7,411,121 |
| Assets | $140.72M |
| Current Assets | $140.46M |
| Noncurrent Assets | $254.92K |
| Liabilities | $2.89M |
| Current Liabilities | $2.74M |
| Noncurrent Liabilities | $154.92K |
| Equity | $137.83M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $137.83M |
| Liabilities And Equity | $140.72M |
| Net Cash Flow From Operating Activities | -$12.20M |
| Net Cash Flow From Operating Activities, Continuing | -$12.20M |
| Net Cash Flow From Investing Activities | -$63.45M |
| Net Cash Flow From Investing Activities, Continuing | -$63.45M |
| Net Cash Flow From Financing Activities | $91.57M |
| Net Cash Flow From Financing Activities, Continuing | $91.57M |
| Net Cash Flow | $15.92M |
| Net Cash Flow, Continuing | $15.92M |
| Comprehensive Income/Loss | -$13.62M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.62M |
| Other Comprehensive Income/Loss | -$13.62M |
| Other Comprehensive Income/Loss Attributable To Parent | $95.40K |